Secondary analysis showed that increases in mean glucagon concentration with tirzepatide versus placebo did not differ in response to induced hypoglycemia from the target PG 100 mg/dL to PG 63 mg/dL and to recovery from the nadir (PG 72 mg/dL) (Table 2). The gene discussed is GCG; the disease is Hypoglycemia.